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Objective: To evaluate risk factors for sudden and unexpected death in epilepsy
(SUDEP) in a high-risk population, i.e. patients treated in a Dutch tertiary referral
center for epilepsy.
Methods: All patients who died between January 1999 and April 2004 while under
treatment of the epilepsy center were identified. Based on clinical data, deaths were
classified as definite, probable, possible or non-SUDEP. Potential risk factors were
compared in SUDEP cases and non-SUDEP cases.
Results: SUDEP incidence was 1.24 per 1000 patient years. SUDEP patients died at a
younger age than patients from the control group of non-SUDEP deaths with epilepsy
and had an earlier onset of epilepsy. However, the frequently mentioned factors in
previous studies, i.e. male sex, generalized tonic—clonic seizures, high seizure
frequency, specific AEDs, polytherapy with several AEDs, mental retardation, psy-
chiatric illness and psychotropic comedication, were not found to be correlated with
SUDEP.
Conclusions: Even in this high-risk population of patients with refractory epilepsy,
treated in a tertiary referral center, SUDEP is not a frequently occurring phenomenon.
Specific risk factors could not be identified within an already high-risk population.
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SUDEP prevention.
In previous studies a number of risk factors has
been identified such as male gender,3,10—15 an age of
20—45 years,9,16,17 generalized tonic—clonic sei-
zures,9—11,15,17—19 high seizure frequency,6,17,20—22
long duration of epilepsy,17,18,22 psychiatric comor-
bidity17,23 and/or mental retardation.4,17,20 In many
cases, there is evidence of a terminal epileptic
seizure.4,11,16,17,19,24—26 SUDEP occurs relatively
more frequently during sleep or while lying in
bed.10,16,19,20,27 It is not clear whether SUDEP occurs
more in symptomatic or idiopathic epilepsy.9,11,15,18
Some authors have shown the influence of specific
antiepileptic drugs (AEDs),15,28,29 in particular those
affecting cardiac rhythm such as sodium channel
blockers. However, in most studies specific AEDs
did not play a role in SUDEP.4,14,16,19,30—32 Also
treatment with multiple AEDs is suggested to be a
risk factor for SUDEP,4,18,22,33 whereas other studies
could not confirm this factor13,15,16,19 or interfering
factors have been found, such as the severity of the
epilepsy.20,34,35
Pathophysiological mechanisms underlying
SUDEP have been suggested to be central
apnea24,30,36—39 or cardiac arrhythmia.37,40—47
The purpose of this study is to evaluate risk
factors for SUDEP in a high-risk population, i.e.
patients treated (both clinically and on an outpa-
tient basis) in a Dutch tertiary referral center for
epilepsy (‘Kempenhaeghe’).Methods
Study population
Epilepsy center Kempenhaeghe in Heeze is a ter-
tiary referral center in the south eastern part of the
Netherlands that provides services for patients
from all parts of our country. The population base
for this study were deaths that occurred within the
epilepsy population treated in the period between
January 1999 and April 2004. The population is
characterized by a high percentage of patients with
severe or intractable epilepsy. In this study, we
compared the SUDEP group with control subjects
with a history of epilepsy who died from other
causes than SUDEP.
SUDEP definition
We used Leestma’s criteria for SUDEP: the victim
suffered from epilepsy, the victim died unexpect-
edly in a reasonable state of health, death occurred
‘suddenly’ (in minutes), when known, deathoccurred during normal activities and benign cir-
cumstances, an obvious medical cause of death was
not found at post-mortem examination and death
was not the direct result of the seizure or status
epilepticus.1,14 ‘Definite SUDEP’ cases meet all cri-
teria, ‘probable SUDEP’ cases meet all criteria but
lack post-mortem data, ‘possible SUDEP’ are cases
where SUDEP cannot be ruled out but available
information is not conclusive and post-mortem data
are lacking, and non-SUDEP are those cases in which
another cause of death is clear or SUDEP is highly
improbable. Working definitions for SUDEP include
both definite and probable SUDEP, because post-
mortem examinations are not routinely performed
in the Netherlands.
Assessment of clinical variables
An electronical patient record system available in
Kempenhaeghe facilitates easy and reliable access
to data for large patient groups. Using this system
the patient’s medical history could be extracted.
For each death the following data were included in a
database and evaluated: epilepsy syndrome, type of
seizures, status epilepticus, age at seizure onset,
seizure frequency in the last year before death,
race, age at death, last AED therapy, comedication
(antihypertensive, pulmonary, cardiac and antipsy-
chotic medication, betablockers, anticoagulants),
comorbidity — such as cardiovascular disease, pul-
monary disease, stroke, diabetes, mental retarda-
tion and psychiatric illness including dementia —
alcohol and other substance abuse, EEG abnormal-
ities, epilepsy localization, circumstances of death
and results of autopsy (if present). Classification of
epilepsy syndrome and seizure type occurred
according to the International League Against Epi-
lepsy system. Family doctors were asked about the
death circumstances when documentation in Kem-
penhaeghe was not conclusive. Data were evaluated
by two neurologists specialized in epilepsy, to cate-
gorize the patients in non-, possible, probable or
definite SUDEP groups. If there was any reason to
suspect that the patient had died of another cause
than SUDEP, for example because of existing comor-
bidity or old age, this patient was included in the
non-SUDEP group.
Statistical analysis
All data were entered in a database and evaluated
using the SPSS statistical program. Descriptives
(means, S.D. and frequencies) were evaluated.
For all variables correlations (crosstabs, with
Chi-square non-parametric testing) between
SUDEP and the clinical variables were calculated.
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tically significant. Those clinical variables that
yielded a statistically significant relationship with
SUDEP the differential contribution was evaluated
with linear regression with SUDEP as the dependent
variable.
Ethics approval was obtained from the ethics
committee of Epilepsy Center Kempenhaeghe,
Heeze.Table 2 Patient dataResults
From January 1999 to April 2004, a mean number of
4400 people with epilepsy were treated per year by
the epilepsy center and 274 deaths were reported at
Kempenhaeghe. Of those, 95 were excluded
because they were not suffering from epilepsy or
they had not been under treatment of Kempen-
haeghe when they died. From the remaining 179
patients, cause of death was not identified in 25
patients, 104 patients died from other causes than
SUDEP, 21 patients were classified as possible SUDEP,
24 as probable SUDEP and five patients died of
definite SUDEP (Table 1). Our SUDEP group consists
of ‘definite plus probable SUDEP’ cases, that is 29
patients. Presuming that the unknown cases were
non-SUDEP, 16.2% of deaths in this period were
caused by SUDEP. A higher percentage would be
the result of omitting the unknown cases from the
analysis (18.8%) or presuming all the unknown cases
are due to SUDEP (30.2%). The 104 patients who died
of other causes than SUDEP form the control group.
Demography
The age at death in the SUDEP group ranged from 4
to 69 years and in the control group 1—90 years. The
SUDEP group was significantly younger than the
control group (mean 29.0  16.0 S.D. versus
52.5  23.1 years with p = 0.016) at time of death.
In the SUDEP group, 45% were male, 55% female
and in the control group 52% male and 48% female.
Although the female proportion was greater in the
SUDEP group, Chi-square analysis indicated that this
was not significant (p = 0.321).Table 1 Cause of death in total study population
Cause of death n = 179 Percentage
Definite SUDEP 5 2.8
Probable SUDEP 24 13.4
Possible SUDEP 21 11.7
Non-SUDEP 104 58.1
Unknown 25 14.0Clinical features
Age at onset of seizures was significantly lower in
SUDEP subjects than in controls (mean 7.68  8.73
years versus 20.69  21.47 years with p < 0.001).
Duration of epilepsy was significantly less in the
SUDEP group than in the control group (mean
19.41  15.86 versus 31.77  24.94 with p = 0.001)
(Table 2).
Number of seizures was not significantly different
between SUDEP cases and controls. In the control
group, relatively more patients were seizure free
for at least 1 year before death, but this was not
significant (p = 0.220).
SUDEP subjects had more generalized tonic—clo-
nic seizures — partial seizures secondarily general-
ized and/or primary generalized tonic—clonic
seizures — than controls, but this was not statisti-
cally significant (p = 0.292). We also performed
statistical analysis for all separate seizure types,
but none of the comparisons reached a statistically
significant correlation with SUDEP. There was no
correlation between SUDEP and type of epilepsy
(divided into idiopathic, symptomatic or crypto-
genic epilepsy); also no correlation was seen
between SUDEP and EEG abnormalities or the loca-
lization of the seizures or other EEG-data.
The SUDEP group showed less comorbidity than
controls. SUDEP subjects had significantly less car-
diovascular and pulmonary disease than controls
(respectively, p = 0.008 and p = 0.046). Stroke and
diabetes mellitus were observed less frequently in
the SUDEP group, but this was not statistically sig-
nificant. Mental retardation and psychiatric illness
occurred slightly more frequently in SUDEP sub-
jects, but this was also not statistically significant.
Medication details
None of the AEDs that were used by the subjects in
this study had a statistically significant correlation
with SUDEP. A combination of sodium channel block-
ers (carbamazepine, oxcarbazepine and phenytoin)





29.00 (15.98) 52.52 (23.12)
Age at onset of
epilepsy (S.D.)
7.68 (8.73) 20.69 (21.45)
Duration of
epilepsy (S.D.)
19.41 (15.86) 31.77 (24.94)
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cant correlation with SUDEP (mean 2.17 in SUDEP
versus 2.16 in non-SUDEP subjects, p = 0.645). In the
SUDEP group, antihypertensive medication was used
significantly less than in the non-SUDEP group
( p = 0.019). In other comedication, in particular
beta-blockers or antipsychotic medication, thereTable 3 SUDEP patients







1 < 69 1.3 IB—IC 1 per month
2 < 31 1.2 IB 4 per month
3 , 47 1.3—2.1 IB—IC 0.7 per month
4 , 42 2.3.1—3 IIB—IID—IIE 1 per month
5 , 54 4.1 IIE—IV 0 per month
6 < 12 1.3 IC 3 per month
7 , 31 1.3 IB—IC—IV 0 per month
8 , 33 1.2—2.3 IB—IIE 0.7 per month
9 , 28 1.3 IB—IC—IV 1 per month
10 < 46 1 IB 0 per month
11 < 31 1.3 IB—IC—IID 20 per month
12 < 23 1.2 IB 0 per month
13 < 33 1.2 IB—IIB—IID 4 per month
14 < 28 1.2 IB—IC 6 per month
15 , 50 1.3 IA—IC 0 per month
16 , 32 1 IB—IC 0.5 per month
17 < 27 2.2 IIE 10 per month
18 , 18 1.2 IC 3.5 per month
19 < 7 1.3 IB 20 per month
20 < 4 1.3 IB—IC—IID 45 per month
21 , 18 1.2 IC 15 per month
22 < 16 1.2 IB—IC 8 per month
23 , 16 1.3 IB—IC 0.1 per month
24 , 55 1.3 IB—IC—IV 2.5 per month
25b < 22 1.3 IB—IC 0.5 per monthwere no statistically significant differences between
SUDEP and non-SUDEP subjects.
Table 3 shows the main characteristics of the 29
SUDEP patients.
For those three factors that reached a statisti-
cally significant correlation with SUDEP, that is age








67 Dinner Died suddenly during
dinner, no seizure
witnessed
22 Morning Found in bed, was
cyanotic; had a fever;
parents had not heard
anything
NA 8.15 a.m. Found in bed on left
side with head in pillow
NA Morning Nocturnal seizures;
found in bed
25 NA Found dead at home
10 Morning Found in bed
NA Morning Found beside the bed
19 NA Found in bed
6 Morning Found in bed; prone
position; head in pillow
NA Morning Found in bed




23 Afternoon Found in bed
NA 7.30 a.m. Hospitalized for a
pneumonia; found in
bed; warm; with bruises
28 NA Found on the ground
beside the sofa
35 Morning Found in bed
27 Morning Found in bed
NA Afternoon Found in bed after nap;
stiffened and cyanotic
18 Afternoon Fever; vomiting; two
seizures; stopped
breathing
6 Morning Found in bed; prone
position; warm
4 NA NAa
NA NA Found at home
8 Morning Found in bed; recently
less seizures
9 NA Found at home
50 12.00 p.m. Went to bed at 5.00 PM
after a seizure; found
in bed; prone position;
head in pillow
4 NA Found in shower
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Table 3 (Continued )













26b , 7 1.2 IB—IIE 30 per month 7 3.20 a.m. Hospitalized for
tonsillitis; found in bed
27b < 10 1.3 IC 1 per month 7 6.53 p.m. Seizures with apneas;
witnessed seizure; apnea
28b , 30 1.3 IC 0.42 per month 7 NA Found in bed; prone
position
29b , 20 1.3 IB—IID 4 per month 20 Morning Found in bed, mouth
with blood and saliva,
incontinent; prone
position
Epilepsy types: 1, partial epilepsy; 1.2, symptomatic partial epilepsy; 1.3, cryptogenic partial epilepsy; 2.1, idiopathic generalized
epilepsy; 2.2, cryptogenic/symptomatic generalized epilepsy; 2.3, symptomatic generalized epilepsy; 2.3.1, symptomatic general-
ized epilepsy with non-specific etiology; 3, undetermined whether focal or generalized epilepsy; 4.1, situation-related seizures.
Seizure types: IA, simple partial seizures; IB, complex partial seizures; IC, partial seizures evolving to secondary generalized seizures;
IIB, myoclonic seizures; IID, tonic seizures; IIE, tonic—clonic seizures; IV, non-epileptic seizures. NA, not available.
a Death was classified probable SUDEP by treating neurologist.
b Definite SUDEP.linear regression analysis was performed. The pre-
viously mentioned factors were used as predictors
and SUDEP as the dependent variable. Regression
analysis was carried out to inspect the differential
contribution of each of these factors in relation to
SUDEP. Regression analysis showed that only one
factor, age at death, correlated statistically signifi-
cantly with SUDEP after removal of the intercorre-
lation between those factors ( p < 0.001;
Beta = 0.370; R square = 0.14), explaining 14% of
the total variance of factors predicting SUDEP.Discussion
In this study we analyzed the correlation between
SUDEP and a wide range of factors reported in
previous studies as risk factors. Our study evaluated
patients, treated in an epilepsy center with a high
percentage of patients suffering from chronic
refractory epilepsy. A high percentage of SUDEP
cases was found (16.2% of the total deaths in the
evaluated period of 5 years and 3 months). We found
a SUDEP rate of 1.24 per 1000 patient years in the
epilepsy population of the epilepsy center. Other
studies report SUDEP rates up to 9.30 per 1000
patient years; highest in cohorts with surgical can-
didates.48 However, in studies performed at epilepsy
centers and epilepsy referrals, SUDEP rates reported
range from 2 to 5.9 per 1000 patient
years.1,12,15,49,50 Our data therefore show a lower
yearly incidence of SUDEP than reported in other
studies. We conclude that SUDEP cannot be consid-
ered as a frequently occurring phenomenon.There were only three differences between the
SUDEP and the non-SUDEP subjects that reached
statistical significance. In the SUDEP group, subjects
died at a significantly younger age than in the non-
SUDEP group. Furthermore, age at onset of epilepsy
was younger than in controls. This finding concurs
with some studies,19,22 but conflicts with other
data.16 The duration of epilepsy was significantly
shorter than in controls. This finding is in contrast
with most previous studies which reported a longer
or no difference in duration of epilepsy in SUDEP
groups compared to controls.11,15,16,50 We believe
that our finding can be partly attributed to the
difference in age at death between SUDEP and
control groups (mean 29.00 years versus mean
52.52 years).
For those three factors that reached a statisti-
cally significant correlation with SUDEP, that is age
at death, age at onset and duration of epilepsy,
linear regression analysis showed that only age
at death correlated statistically significantly
with SUDEP. Our finding that the SUDEP group was
significantly younger than the control group
concurs with most previous studies that indicated
young adults to be particularly at risk for
SUDEP.3,9,11,14,16,17,50
Young (adult) age at death can however not be
seen as a real risk factor for SUDEP. Part of this
difference in age at death can be explained by the
definition of SUDEP. In elderly people deaths are
more likely to be attributed to the presence of
comorbidity, for example cardiovascular or pulmon-
ary disease, or to old age itself which causes that
SUDEP in the higher age ranges will go undetected.
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commonly in male subjects,3,10—13,15 but some like
our study find no association between SUDEP and
gender.19
Most of the SUDEP subjects had generalized
tonic—clonic seizures (76%), confirming previous
studies,4,9—11,15,17,19,30,47 although this differed
not much from the control group (68%).
We could not confirm previous studies that
reported a correlation between SUDEP and particu-
lar epilepsy types,9,15,18 in agreement with two
other studies.11,16 Where most studies reported
higher SUDEP occurrence in subjects with frequent
seizures,2,14,15,17,22,50,51 some like our study find no
correlation between SUDEP and a high seizure fre-
quency.15,16,19 We could not prove a significant dif-
ference in epilepsy localization between SUDEP and
non-SUDEP subjects.
No significant differences were found in comor-
bidity. Cardiovascular and pulmonary disease was
reported less in the SUDEP subjects than in controls,
but we believe this can be attributed to the age
differences and to SUDEP definitions. Subjects with
major comorbidity were more likely to be diagnosed
as possible or non-SUDEP than healthy subjects.
Mental retardation and psychiatric illness were
reported slightly more in the SUDEP group, but this
was not significant. These findings are in contrast
with previous reports of association of SUDEP with
mental retardation4,17,20 and psychiatric ill-
ness,17,23 but agree with another study that did
not confirm an association.16
We found no significant differences in medication
between SUDEP and control groups. No particular
AED was associated with SUDEP, confirming previous
studies,16,17,19,30 but in contrast with other stu-
dies.28,35,52 Polytherapy with AEDs was not con-
firmed to be a risk factor for SUDEP, in agreement
with previous reports,13,16,19,28 but differing from
other studies.4,22,30,33 This finding may be related to
the high percentage of subjects with severe epi-
lepsy, and as a consequence a high percentage of
subjects on polytherapy, in both the SUDEP as the
control groups. In comedication, SUDEP subjects
used significantly less antihypertensive medication,
probably as a result of both younger age and less
cardiovascular disease in this group. Other comedi-
cation did not differ appreciably between our
groups. In particular, this contrasts with previous
findings that psychotropic medication is likely to be
associated with SUDEP.33
Previous studies reported signs of seizures, for
example fresh bites, cyanosis or blood on the pillow,
preceding death in most of SUDEP subjects.11,14,16,19
In our study, we also see a trend towards deaths
preceded by seizures, but data were not sufficientto compare with the control group. However, SUDEP
did also occur in subjects who had been seizure free
in the last 12 months before their death. Most of the
SUDEP subjects were found in bed and where posi-
tion at death was reported, prone position was
frequently the case. Unfortunately, we cannot com-
pare these findings with results from the control
group, because these data are lacking about the
control subjects.
In conclusion even in this high-risk population of
patients with a refractory epilepsy, treated in a
tertiary referral center, SUDEP occurs a fourfold
times more than in the overall population of epi-
lepsy patients, but is not as frequent as reported in
other studies with highly selected patients popula-
tions. In absolute numbers it is not a frequently
occurring phenomenon with a yearly incidence of
1.24/1000. Our study showed that SUDEP patients
died at a younger age than a control group of non-
SUDEP deaths with epilepsy and had an earlier onset
of epilepsy but no real risk factors could be identi-
fied. The frequently mentioned factors in previous
studies, i.e. male gender, generalized tonic—clonic
seizures, high seizure frequency, particular AEDs,
polytherapy of AEDs, mental retardation, psychia-
tric illness and psychotropic comedication, were not
found to be correlated with SUDEP in our study.References
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